Interview: Why Europe’s Biotech ‘Prime Time’ Is Now
VC Firm Sofinnova’s Chair Papiernik Speaks After New Fund Launch
Executive Summary
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.